{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:00:19Z","timestamp":1782190819008,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100025287","name":"Center for Forecasting and Outbreak Analytics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.vaccine.2024.126516","type":"journal-article","created":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T18:45:15Z","timestamp":1732473915000},"page":"126516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P2","title":["Poor vaccine responders mask the true trend in vaccine effectiveness against progression to severe disease"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3884-0921","authenticated-orcid":false,"given":"Natalie E.","family":"Dean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-1757","authenticated-orcid":false,"given":"M. Elizabeth","family":"Halloran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3096-3695","authenticated-orcid":false,"given":"Veronika I.","family":"Zarnitsyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126516_bb0005","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza A virus infection and vaccination","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2024.126516_bb0010","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.126516_bb0015","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1164\/rccm.201411-1988OC","article-title":"Natural t cell\u2013mediated protection against seasonal and pandemic influenza. results of the flu watch cohort study","volume":"191","author":"Hayward","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2024.126516_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12050491","article-title":"Induction of superior systemic and mucosal protective immunity to SARS-CoV-2 by nasal administration of a VSV\u2013\u0394G\u2013spike vaccine","volume":"12","author":"Yahalom-Ronen","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2024.126516_bb0025","series-title":"Design and analysis of vaccine studies","first-page":"1","author":"Halloran","year":"2010"},{"key":"10.1016\/j.vaccine.2024.126516_bb0030","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3201\/eid2903.221367","article-title":"Comparative effectiveness of covid-19 vaccines in preventing infections and disease progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal","volume":"29","author":"Kislaya","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126516_bb0035","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1093\/cid\/ciac439","article-title":"Effectiveness of the Ad26.COV2.S (Johnson & Johnson) coronavirus disease 2019 (COVID-19) vaccine for preventing COVID-19 hospitalizations and progression to high disease severity in the United States","volume":"75","author":"Lewis","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126516_bb0040","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.abe6959","article-title":"Model-informed COVID-19 vaccine prioritization strategies by age and serostatus","volume":"371","author":"Bubar","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.126516_bb0045","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126516_bb0500","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa2117128","article-title":"Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina","volume":"386","author":"Lin","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2024.126516_bb0050","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10654-022-00911-3","article-title":"Estimating conditional vaccine effectiveness","volume":"37","author":"JPA","year":"2022","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vaccine.2024.126516_bb0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1198\/016214505000000970","article-title":"Causal vaccine effects on binary postinfection outcomes","volume":"101","author":"Hudgens","year":"2006","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.vaccine.2024.126516_bb0060","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/1541-0420.00063","article-title":"Sensitivity analysis for the assessment of causal vaccine effects on viral load in hiv vaccine trials","volume":"59","author":"Gilbert","year":"2003","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2024.126516_bb0065","first-page":"13","article-title":"Individuals with weaker antibody responses after booster immunization are prone to omicron breakthrough infections","author":"M\u00f6hlendick","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.126516_bb0070","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.immuni.2021.09.019","article-title":"Transition to endemicity: Understanding COVID-19","volume":"54","author":"Antia","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2024.126516_bb0075","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00251-023-01294-9","article-title":"Role of T cells in severe COVID-19 disease, protection, and long term immunity","volume":"75","author":"Hermens","year":"2023","journal-title":"Immunogenetics"},{"key":"10.1016\/j.vaccine.2024.126516_bb0080","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41577-022-00716-1","article-title":"Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?","volume":"22","author":"Kent","year":"2022","journal-title":"Nat Rev Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24011988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24011988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T03:21:23Z","timestamp":1734492083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24011988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":17,"alternative-id":["S0264410X24011988"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126516","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poor vaccine responders mask the true trend in vaccine effectiveness against progression to severe disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126516"}}